Results 161 to 170 of about 82,443 (252)

Examining the role of freebase nicotine in the harm reduction potential of oral nicotine pouches versus moist snuff: A randomized crossover trial

Addiction, EarlyView.
Abstract Background and aims Oral nicotine pouches (ONPs) contain varying proportions of freebase nicotine (FBN), with higher FBN expected to increase nicotine delivery across the oral mucosa. Because ONPs contain fewer toxicants than moist snuff and may serve as a reduced harm alternative for smokeless tobacco, we compared how the FBN in ONPs affects ...
Brittney Keller‐Hamilton, Hayley Curran, Leanne Atkinson, Sriya Suraapaneni, Alice Hinton, Kirsten Chrzan, Darren Mays, Ahmad El‐Hellani, Clark W. Wilson, Marielle C. Brinkman, Theodore L. Wagener   +10 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Nicotine pouches and clinical outcomes related to smoking cessation: A systematic review of randomized trials

Addiction, EarlyView.
Abstract Background and aims Tobacco‐free nicotine pouches (NPs) are oral nicotine products promoted by manufacturers and some researchers as tools that may reduce nicotine cravings and support smoking reduction or cessation. However, evidence regarding their actual clinical impact remains limited.
Javad Heshmati, Spencer Shahen, Emma Lynn Bates, Sarah Visintini, Evyanne Quirouette, Kerri‐Anne Mullen, Hassan Mir   +6 more
wiley   +1 more source

Clinical and psychosocial factors predicting persistent smoking in hospitalized patients with atherosclerotic vascular disease: A prespecified analysis of two randomized controlled trials. [PDF]

Tob Prev Cessat
Getz V, Pleym K, Dammen T, Husebye E, Sverre E, Papageorgiou C, Weedon-Fekjær H, Munkhaugen J.   +7 more
europepmc   +1 more source

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol‐free and low‐alcohol products in higher risk groups

Addiction, EarlyView.
Abstract Alcohol‐free and low‐alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high‐income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol‐related health problems should take a zero‐tolerance approach to these alcohol‐like products or encourage patients to ...
John Holmes, Christopher K. Oldroyd, Colin Drummond, Matt Field, Inge Kersbergen, Michael E. D. Allison   +5 more
wiley   +1 more source

Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials. [PDF]

Thorax
Prochaska J, Rubinstein M, Perdok R, Blumenstein B, Jacobs C.   +4 more
europepmc   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Recompensation following first decompensation in patients with alcohol-related cirrhosis. [PDF]

BMC Gastroenterol
Kwak JY, Jeon H, Kwon HU, Kim JE, Han JH, Choi JW, Cha RR, Lee JM, Lee SS.   +8 more
europepmc   +1 more source

Appetitive responses toward smoking‐related stimuli in abstinence‐motivated, non‐deprived individuals with chronic tobacco dependence: A multi‐methodological investigation

Addiction, EarlyView.
Abstract Background and aims Appetitive responses, such as approach biases, are thought to play a crucial role in smoking. This study aimed to compare responses toward smoking‐related stimuli with responses in control conditions (e.g. non‐approach or neutral stimuli) using a multi‐method approach. By examining associations between response measures and
Franziska Motka, Haoye Tan, Seth M. Levine, Sabine Vollstädt‐Klein, Sarah K. Danböck, Katja Bertsch, Markus H. Winkler, Charlotte E. Wittekind   +7 more
wiley   +1 more source